XML 43 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
Marketable Securities and Fair Value Measurements (Tables)
9 Months Ended
Dec. 31, 2017
Fair Value Disclosures [Abstract]  
Marketable Securities

The Company’s marketable securities at December 31, 2017 and March 31, 2017 are invested in the following:

 

 

 

Amortized

 

 

Gross

Unrealized

 

 

Gross

Unrealized

 

 

Fair Market

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Value

 

 

 

(in $000's)

 

December 31, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term U.S. Treasury mutual fund securities

 

$

21,068

 

 

$

 

 

$

(25

)

 

$

21,043

 

Short-term government-backed securities

 

 

152,586

 

 

 

 

 

 

(343

)

 

 

152,243

 

Short-term corporate debt securities

 

 

77,592

 

 

 

3

 

 

 

(130

)

 

 

77,465

 

Long-term government-backed securities

 

 

47,587

 

 

 

 

 

 

(96

)

 

 

47,491

 

Long-term corporate debt securities

 

 

1,997

 

 

 

 

 

 

(3

)

 

 

1,994

 

 

 

$

300,830

 

 

$

3

 

 

$

(597

)

 

$

300,236

 

 

 

 

Amortized

 

 

Gross

Unrealized

 

 

Gross

Unrealized

 

 

Fair Market

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Value

 

 

 

(in $000's)

 

March 31, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term U.S. Treasury mutual fund securities

 

$

45,199

 

 

$

 

 

$

(13

)

 

$

45,186

 

Short-term government-backed securities

 

 

90,199

 

 

 

1

 

 

 

(87

)

 

 

90,113

 

Short-term corporate debt securities

 

 

55,465

 

 

 

 

 

 

(31

)

 

 

55,434

 

Long-term U.S. Treasury mutual fund securities

 

 

1,998

 

 

 

 

 

 

(3

)

 

 

1,995

 

Long-term government-backed securities

 

 

43,484

 

 

 

5

 

 

 

(18

)

 

 

43,471

 

Long-term corporate debt securities

 

 

1,853

 

 

 

 

 

 

(1

)

 

 

1,852

 

 

 

$

238,198

 

 

$

6

 

 

$

(153

)

 

$

238,051

 

 

Financial Instruments Recorded at Fair Value

The following table presents the Company’s financial instruments recorded at fair value in the condensed consolidated balance sheets, classified according to the three categories described above:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

December 31, 2017:

 

(in $000's)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term U.S. Treasury mutual fund securities

 

$

 

 

$

21,043

 

 

$

 

 

$

21,043

 

Short-term government-backed securities

 

 

 

 

 

152,243

 

 

 

 

 

 

152,243

 

Short-term corporate debt securities

 

 

 

 

 

77,465

 

 

 

 

 

 

77,465

 

Long-term government-backed securities

 

 

 

 

 

47,491

 

 

 

 

 

 

47,491

 

Long-term corporate debt securities

 

 

 

 

 

1,994

 

 

 

 

 

 

1,994

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

 

 

 

 

 

 

 

10,423

 

 

 

10,423

 

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

March 31, 2017:

 

(in $000's)

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term U.S. Treasury mutual fund securities

 

$

 

 

$

45,186

 

 

$

 

 

$

45,186

 

Short-term government-backed securities

 

 

 

 

 

90,113

 

 

 

 

 

 

90,113

 

Short-term corporate debt securities

 

 

 

 

 

55,434

 

 

 

 

 

 

55,434

 

Long-term U.S. Treasury mutual fund securities

 

 

 

 

 

1,995

 

 

 

 

 

 

1,995

 

Long-term government-backed securities

 

 

 

 

 

43,471

 

 

 

 

 

 

43,471

 

Long-term corporate debt securities

 

 

 

 

 

1,852

 

 

 

 

 

 

1,852

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

 

 

 

 

 

 

 

9,153

 

 

 

9,153

 

 

Valuation Method Used to Calculate Level 3 Liabilities Measured at Estimated Fair Value of Contingent Consideration Related to Acquisition

This liability is reported as Level 3 as the estimated fair value of the contingent consideration related to the acquisition of ECP requires significant management judgment or estimation and is calculated using the following valuation methods:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value at December 31, 2017 (in $000's)

 

 

Valuation Methodology

 

Significant Unobservable Input

 

Weighted Average (range, if applicable)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical and regulatory milestone

 

$

5,654

 

 

Probability

weighted income approach

 

Projected fiscal year of milestone payments

 

2019 to 2022

 

 

 

 

 

 

 

 

 

Discount rate

 

2.8% to 3.3%

 

 

 

 

 

 

 

 

 

 

Probability of occurrence

 

Probability adjusted level of 40% for the base case scenario and 12% to 30% for various upside and downside scenarios

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue-based milestone

 

 

4,769

 

 

Monte Carlo simulation model

 

Projected fiscal year of milestone payments

 

2023 to 2035

 

 

 

 

 

 

 

 

 

Discount rate

 

 

18%

 

 

 

 

 

 

 

 

 

Expected volatility for forecasted revenues

 

 

50%

 

 

 

$

10,423

 

 

 

 

 

 

 

 

 

 

Change in Fair Value of Contingent Consideration as Determined by Level 3 Inputs

 

The following table summarizes the change in fair value, as determined by Level 3 inputs, of the contingent consideration for the three and nine months ended December 31, 2017 and 2016:

 

 

 

For the Three Months Ended December 31,

 

 

For the Nine Months Ended December 31,

 

 

 

 

2017

 

 

 

2016

 

 

 

2017

 

 

 

2016

 

 

 

(in $000's)

 

 

(in $000's)

 

Level 3 liabilities, beginning balance

 

$

9,835

 

 

$

7,749

 

 

$

9,153

 

 

$

7,563

 

Additions

 

 

 

 

 

 

 

 

 

 

 

 

Payments

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value

 

 

588

 

 

 

426

 

 

 

1,270

 

 

 

612

 

Level 3 liabilities, ending balance

 

$

10,423

 

 

$

8,175

 

 

$

10,423

 

 

$

8,175